Category:
API Equipment
Standard:
N;
China GMP
Form: tablet
Strength: 20mg, 50mg
Indication: newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase; chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate.
This category refers to oral therapeutic tablets designed for systemic treatment. Manufactured under strict GMP standards, these products utilize purified active pharmaceutical ingredients combined with standard excipients to ensure stability and bioavailability.